Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin immunotherapy
Despite its higher acquisition cost, the inclusion of nadofaragene firadenovec resulted in a minimal budget impact as bladder-sparing option for patients with BCG-unresponsive NMIBC with CIS ± Ta/T1.
Authors
- Ashton Moradi
- Y. Lotan
- Angela Zhao (ORCID: https://orcid.org/0009-0004-5019-9094)
- Xinglei Chai
- Dongni Ye
- Min Yang
Institutions
- Ferring Pharmaceuticals (Switzerland) (CH)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1080/13696998.2026.2630599
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00